326 related articles for article (PubMed ID: 21828134)
1. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
[TBL] [Abstract][Full Text] [Related]
2. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
3. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
5. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
Itzykson R; Santini V; Thepot S; Ades L; Chaffaut C; Giagounidis A; Morabito M; Droin N; Lübbert M; Sapena R; Nimubona S; Goasguen J; Wattel E; Zini G; Torregrosa Diaz JM; Germing U; Pelizzari AM; Park S; Jaekel N; Metzgeroth G; Onida F; Navarro R; Patriarca A; Stamatoullas A; Götze K; Puttrich M; Mossuto S; Solary E; Gloaguen S; Chevret S; Chermat F; Platzbecker U; Fenaux P
J Clin Oncol; 2023 Apr; 41(10):1888-1897. PubMed ID: 36455187
[TBL] [Abstract][Full Text] [Related]
6. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
Aucagne R; Droin N; Paggetti J; Lagrange B; Largeot A; Hammann A; Bataille A; Martin L; Yan KP; Fenaux P; Losson R; Solary E; Bastie JN; Delva L
J Clin Invest; 2011 Jun; 121(6):2361-70. PubMed ID: 21537084
[TBL] [Abstract][Full Text] [Related]
7. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
9. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
[TBL] [Abstract][Full Text] [Related]
10. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
11. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
13. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
14. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Oki Y; Jelinek J; Shen L; Kantarjian HM; Issa JP
Blood; 2008 Feb; 111(4):2382-4. PubMed ID: 18055864
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
[TBL] [Abstract][Full Text] [Related]
16. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
Santini V; Allione B; Zini G; Gioia D; Lunghi M; Poloni A; Cilloni D; Sanna A; Masiera E; Ceccarelli M; Abdel-Wahab O; Terenzi A; Angelucci E; Finelli C; Onida F; Pelizzari A; Ferrero D; Saglio G; Figueroa M; Levis A
Leukemia; 2018 Feb; 32(2):413-418. PubMed ID: 28607470
[TBL] [Abstract][Full Text] [Related]
17. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
18. Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
Gu J; Wang Z; Xiao M; Mao X; Zhu L; Wang Y; Huang W
Cancer Biol Ther; 2017 Nov; 18(11):843-849. PubMed ID: 28102729
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
Duchmann M; Yalniz FF; Sanna A; Sallman D; Coombs CC; Renneville A; Kosmider O; Braun T; Platzbecker U; Willems L; Adès L; Fontenay M; Rampal R; Padron E; Droin N; Preudhomme C; Santini V; Patnaik MM; Fenaux P; Solary E; Itzykson R
EBioMedicine; 2018 May; 31():174-181. PubMed ID: 29728305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
